You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

pemafibrate

Showing 1 - 8 of 8
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hypercholesterolemia Trial in Japan (K-877 0.2 mg/day (once daily), K-877 0.4 mg/day (once daily), Placebo (once daily))

Recruiting
  • Hypercholesterolemia
  • K-877 0.2 mg/day (once daily)
  • +2 more
  • Aichi, Japan
  • +14 more
Jun 20, 2023

Dyslipidemias Trial in Japan (K-877 ER 0.2 mg/day morning administration (once daily), K-877 ER 0.2 mg/day evening

Completed
  • Dyslipidemias
  • K-877 ER 0.2 mg/day morning administration (once daily)
  • K-877 ER 0.2 mg/day evening administration (once daily)
  • Fukuoka, Japan
  • +13 more
Aug 8, 2022

Dyslipidemias Trial in Kanagawa, Osaka, Tokyo (K-877 ER 0.2 mg/day (once daily), K-877 ER 0.4 mg/day (once daily), K-877 IR 0.2

Completed
  • Dyslipidemias
  • K-877 ER 0.2 mg/day (once daily)
  • +2 more
  • Kanagawa, Japan
  • +10 more
Dec 2, 2021

Dyslipidemias Trial in Osaka (K-877 IR 0.2 mg/day, K-877 CR 0.4 mg/day, K-877 CR 0.8 mg/day)

Completed
  • Dyslipidemias
  • K-877 IR 0.2 mg/day
  • +2 more
  • Osaka, Japan
    Medical Corporation Heishinkai OPHAC Hospital
Apr 8, 2021

Non-Alcoholic Fatty Liver Disease Trial in Japan (K-877, Placebo)

Completed
  • Non-Alcoholic Fatty Liver Disease
  • Aomori, Aomori, Japan
  • +15 more
Apr 8, 2021

Hyperlipidemia Trial in China (K-877 0.1 mg tablet, Fenofibrate 200 mg capsule, Placebo tablet)

Recruiting
  • Hyperlipidemia
  • K-877 0.1 mg tablet
  • +3 more
  • Anhui, China
  • +32 more
Dec 8, 2021

Type2 Diabetes, Dyslipidemia Trial in Worldwide (K-877, Placebo)

Terminated
  • Type2 Diabetes
  • Dyslipidemia
  • Birmingham, Alabama
  • +887 more
Dec 20, 2022

Diabetic Retinopathy, Diabetic Macular Edema Trial in Canada, United States (Pemafibrate, Placebo)

Terminated
Has Results
  • Diabetic Retinopathy
  • Diabetic Macular Edema
  • Pemafibrate
  • Placebo
  • Phoenix, Arizona
  • +70 more
Aug 27, 2020